H1_CTR1-mEos4b
WAe001-A-79
General
Cell Line |
|
hPSCreg name | WAe001-A-79 |
Cite as: | WAe001-A-79 (RRID:CVCL_C0C9) |
Alternative name(s) |
H1_CTR1-mEos4b
|
Cell line type | Human embryonic stem cell (hESC) |
Similar lines |
WAe001-A (WA01, H1) WAe001-A-31 (H1_RB1ex1_D6) WAe001-A-32 (H1_RB1ex1_E9) WAe001-A-87 (H1.213, H1.2-13) WAe001-A-G (H1X-10/H1.5-1) WAe001-A-88 (H1.2-124, H1.2124) WAe001-A-1N (H1-FIS1-KO, WA01-FIS1-KO) WAe001-A-89 (H1.3-64, H1.364) WAe001-A-H (H1X-59/H1.5-33) WAe001-A-1O (WA01-MYB-KO, H1-MYB-KO) WAe001-A-77 (H1 RYBP-FLAG-HA KI) WAe001-A-90 (H1.3-191, H1.3191) WAe001-A-I (H1.0-29/H1.1-13) WAe001-A-41 (H1-RNF2-KO-1#) WAe001-A-J (H1.0-102/H1.1-34) WAe001-A-42 (H1-RNF2-KO-2#) WAe001-A-K (H1.0-29/H1.2-31) WAe001-A-1 (H1.1, WA01.1) WAe001-A-L (H1.0-102/H1.2-6) WAe001-A-M (H1.0-29/H1.3-22) WAe001-A-N (H1.0-102/H1.3-90) WAe001-A-91 (H1.4-126, H1.4126) WAe001-A-O (H1.0-29/H1.4-14) WAe001-A-92 (H1.4-143, H1.4143) WAe001-A-P (H1.0-102/H1.4-19) WAe001-A-93 (H1.5-23, H1.523) WAe001-A-78 (H1X10, H1X-10) WAe001-A-94 (H1.528, H1.5-28) WAe001-A-Q (H1.0-29/H1.5-6) WAe001-A-73 (H1-GATAD2B-KO-79#) WAe001-A-R (H1.0-102/H1.5-44) WAe001-A-10 (H1_RB1ex3_G3) WAe001-A-74 (H1-GATAD2B-KO-81#) WAe001-A-S (H1.1-17/H1.2-11) WAe001-A-11 (H1_RB1ex3_G4) WAe001-A-T (H1.1-39/H1.2-9) WAe001-A-U (H1.1-17/H1.4-18) WAe001-A-A (H1X-10/H1.2-20) WAe001-A-2B (H1-NSD2-/-) WAe001-A-B (H1X-59/H1.2-6) WAe001-A-C (H1X-10/H1.3-62) WAe001-A-D (H1X-59/H1.3-68) WAe001-A-E (H1X-10/H1.4-4) WAe001-A-F (H1X-59/H1.4-5) WAe001-A-86 (H1.139, H1.1-39) WAe001-A-72 (H1-FTO-Knockout-13) |
Last update | 16th June 2022 |
User feedback | |
Provider |
|
Generator | University of Houston - Main Campus (UHMC) |
External Databases |
|
BioSamples | SAMEA14370583 |
Cellosaurus | CVCL_C0C9 |
Wikidata | Q112930550 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclone of |
Donor Information
General Donor Information |
|
Sex | male |
Ethnicity | N/A |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Family history | NO |
Is the medical history available upon request? | NO |
Is clinical information available? | NO |
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
All cell lines of this donor's relatives |
Has brother:
|
External Databases (Donor) |
|
BioSamples | SAMEA7767418 |
Ethics
Also have a look at the ethics information for the parental line
WAe001-A
.
hESC Derivation
The source cell information can be found in the parental cell line
WAe001-A.
|
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzymatically
Accutase
|
CO2 Concentration | 5 % |
Medium |
mTeSR™ Plus
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
|
|||
SOX2 |
Yes |
|
|
|||
POU5F1 (OCT-4) |
Yes |
|
|
Differentiation Potency
In vitro directed differentiation
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
A total of 22 metaphases were karyotyped by G-banding: 16 showed normal 46, XY. 2 showed 45, XY, t(14q:14q). 1 showed 44,X, -Y, t(14q;14q). 1 showed 45, X, -Y. 1 showed 47, XY, -4, break in centromeric region of chr 4. 1 showed 47, XY, -9, break in centromeric region of chr 9.
Passage number: 11
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Genetic Modification
Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.